A. M. Mikhailova
Research Subjects
A. M. Mikhailova has a total of 8 co-authors. Here are the top co-authors by number of shared publications:
- Alexandr R. Shin
N.N. Blokhin National Medical Research Center of Oncology
1 shared publication - J. Zhao
I.M. Sechenov First Moscow State Medical University, Ministry of Health of Russia (Sechenov University)
1 shared publication - M.R. Chiaureli
A.N. Bakulev Center for Cardiovascular Surgery of the Russian Ministry of Health
1 shared publication - Maryam R. Tamrazova
Blokhin National Medical Research Center of Oncology
1 shared publication - Merab M. Gabrava
N.N. Blokhin National Medical Research Center of Oncology
1 shared publication V. Y. Bokhian
N.N. Blokhin National Medical Research Center of Oncology
1 shared publication
Latest Publications
- 1 February 2026
- Published by Endocrinology Research Centre in Endocrine Surgery
- Vol. 19 (3) , 54-62
Pheochromocytomas and paragangliomas in patients with congenital heart defects
The correlation between pheochromocytoma/paraganglioma (PHEO/PGL) and cyanotic congenital heart defects is rare but not coincidental. Research suggests that the development of PHEO/PGL in these patients maybe explained by chronic hypoxia, disruptions in the sympathetic nervous system, and potential genetic predisposition. These factors may provoke the tumor transformation of chromaffin cells. Additionally, diagnosing PHEO/PGL in patients with heart defects is complicated by hemodynamic disturbances that mask the characteristic sympathoadrenal crises of PHEO/PGL. The occurrence of these neoplasms can exacerbate the clinical course of congenital defects due to increased catecholamine secretion, leading to vasoconstriction and worsening hypoxia. We present two clinical cases of PHEO/PGL in the context of congenital heart defects, with patients observed and treated at the N.N. Blokhin National Medical Research Center of Oncology and the A.N. Bakoulev National Medical Research Center of Cardiovascular Surgery. These observations emphasize the importance of vigilance for symptoms of tachycardia and uncontrolled hypertension in such patients. Despite their rarity, the relationship between these pathologies must be considered for accurate diagnosis and optimal treatment selection.
- 1 February 2026
- Published by Endocrinology Research Centre in Endocrine Surgery
- Vol. 19 (3) , 54-62
Pheochromocytomas and paragangliomas in patients with congenital heart defects
The correlation between pheochromocytoma/paraganglioma (PHEO/PGL) and cyanotic congenital heart defects is rare but not coincidental. Research suggests that the development of PHEO/PGL in these patients maybe explained by chronic hypoxia, disruptions in the sympathetic nervous system, and potential genetic predisposition. These factors may provoke the tumor transformation of chromaffin cells. Additionally, diagnosing PHEO/PGL in patients with heart defects is complicated by hemodynamic disturbances that mask the characteristic sympathoadrenal crises of PHEO/PGL. The occurrence of these neoplasms can exacerbate the clinical course of congenital defects due to increased catecholamine secretion, leading to vasoconstriction and worsening hypoxia. We present two clinical cases of PHEO/PGL in the context of congenital heart defects, with patients observed and treated at the N.N. Blokhin National Medical Research Center of Oncology and the A.N. Bakoulev National Medical Research Center of Cardiovascular Surgery. These observations emphasize the importance of vigilance for symptoms of tachycardia and uncontrolled hypertension in such patients. Despite their rarity, the relationship between these pathologies must be considered for accurate diagnosis and optimal treatment selection.
- Open Access
- 3 November 2025
- Published by Publishing House ABV Press in Head and Neck Tumors (HNT)
- Vol. 15 (3) , 50-58
The impact of antitumor effect severity on the long-term results of treatment of patients with locally advanced squamous cell carcinoma of the nasal cavity and paranasal sinuses
Introduction. Squamous cell carcinoma of the nasal cavity and paranasal sinuses is one of the rare malignancies. In about 80 % of cases, this pathology is diagnosed at stage III–Iv, which causes an unfavorable prognosis of the disease.Aim. To evaluate effectiveness of an integrated approach to treatment of stage III–Iv squamous cell carcinoma of the nasal cavity and paranasal sinuses.Materials and methods. The study included 126 patients with locally advanced squamous cell carcinoma of the nasal cavity and paranasal sinuses who were treated and observed during 2000–2020 at the N. N. Blokhin National medical Research Center for Oncology. Depending on the choice of treatment tactics at the 1st stage, patients were divided into 3 groups. group 1 (n = 55) included patients who underwent conservative treatment (radiation or chemoradiation) therapy in an independent version, group 2 (n = 31) – patients who underwent surgery with adjuvant radiation therapy, group 3 (n = 40) – patients who underwent induction radiation or chemoradiation therapy with subsequent surgery. Results. Overall 5-year survival rates did not differ between the 3 groups (p 0.05). At the same time, 5-year progression-free survival in group 2 (surgery + adjuvant radiation or chemoradiation therapy) was significantly higher (50.5 %) as compared with groups 1 (conservative treatment) (17 %; p = 0.021) and 3 (induction radiation or chemoradiation therapy + surgery) (25.5 %; p = 0.031). The five-year progression-free survival of patients with T3 tumor in group 2 was 59.4 %, which was significantly higher than in groups 1 (17.9 %; p = 0.021) and 3 (27.1 %; p = 0.031). However, there were no between-group differences in progression-free survival in patients with T4 tumor.Conclusion. Local recurrence is the most common cause of disease progression. Surgery with adjuvant radiation therapy, especially in patients with T3 tumor, improves the prognosis of the disease. At the same time, it is advisable to conduct conservative treatment to patients with T4 tumor.
- 3 November 2025
- Published by Publishing House ABV Press in Head and Neck Tumors (HNT)
- Vol. 15 (3) , 50-58
Open AccessThe impact of antitumor effect severity on the long-term results of treatment of patients with locally advanced squamous cell carcinoma of the nasal cavity and paranasal sinuses
Introduction. Squamous cell carcinoma of the nasal cavity and paranasal sinuses is one of the rare malignancies. In about 80 % of cases, this pathology is diagnosed at stage III–Iv, which causes an unfavorable prognosis of the disease.Aim. To evaluate effectiveness of an integrated approach to treatment of stage III–Iv squamous cell carcinoma of the nasal cavity and paranasal sinuses.Materials and methods. The study included 126 patients with locally advanced squamous cell carcinoma of the nasal cavity and paranasal sinuses who were treated and observed during 2000–2020 at the N. N. Blokhin National medical Research Center for Oncology. Depending on the choice of treatment tactics at the 1st stage, patients were divided into 3 groups. group 1 (n = 55) included patients who underwent conservative treatment (radiation or chemoradiation) therapy in an independent version, group 2 (n = 31) – patients who underwent surgery with adjuvant radiation therapy, group 3 (n = 40) – patients who underwent induction radiation or chemoradiation therapy with subsequent surgery. Results. Overall 5-year survival rates did not differ between the 3 groups (p 0.05). At the same time, 5-year progression-free survival in group 2 (surgery + adjuvant radiation or chemoradiation therapy) was significantly higher (50.5 %) as compared with groups 1 (conservative treatment) (17 %; p = 0.021) and 3 (induction radiation or chemoradiation therapy + surgery) (25.5 %; p = 0.031). The five-year progression-free survival of patients with T3 tumor in group 2 was 59.4 %, which was significantly higher than in groups 1 (17.9 %; p = 0.021) and 3 (27.1 %; p = 0.031). However, there were no between-group differences in progression-free survival in patients with T4 tumor.Conclusion. Local recurrence is the most common cause of disease progression. Surgery with adjuvant radiation therapy, especially in patients with T3 tumor, improves the prognosis of the disease. At the same time, it is advisable to conduct conservative treatment to patients with T4 tumor.